COMMUNIQUÉS West-GlobeNewswire

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
REVTORPYK™ (gedatolisib) approved by the U.S. FDA for the treatment of HR+/HER2- PIK3CA Wild-Type locally advanced or metastatic breast cancer on July 14, 2026; on track for commercial launch late third quarter 2026 [...]
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results
13/08/2026
Independent Blinded Survey of 50 Plastic Surgeons Validates Demand; NXT-41 and NXT-41x Remain On-Track Funded through launch: secured up to $26 million of capital without an equity offering The unmet need is real: 86% [...]
Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
13/08/2026
Enrollment and dosing completed in Cohort 1 of Phase 1b registrational study of SER-252 - Top-line data from the single-ascending-dose arm targeted for the first half of 2027 - Appointment of Farrell Simon, Pharm.D., to [...]
Profound Medical Launches ‘Let's Huddle’, a Global Community Supporting Men Throughout Their Prostate Care Journey
13/08/2026
A patient-centered initiative focused on education, connection, and support TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage [...]
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
13/08/2026
Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding PONTE VEDRA, Fla., Aug. 13, 2026 ( [...]
Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform
13/08/2026
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated [...]
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
13/08/2026
TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported [...]
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
13/08/2026
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates [...]
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
13/08/2026
Executed a development collaboration with Senlang Biotechnology to advance certain in vivo CAR-T product candidates, including TPST-4003, a CD7-targeted next-generation in vivo CAR-T, with first patient dosing [...]
Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
13/08/2026
Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study targeting first patient dosing in Q1 2027 Showcased the [...]
Maze Therapeutics Announces Appointments to Its Board of Directors
13/08/2026
Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., join Maze’s Board of Directors, adding to the Company’s deep bench of clinical and industry experience SOUTH SAN FRANCISCO, Calif., Aug. 13, 2026 ( [...]
Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
13/08/2026
DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial [...]
NovaBridge to Report First Half 2026 Financial Results and Provide a Corporate Update on Thursday, August 20, 2026
13/08/2026
ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology company that identifies differentiated innovation and applies disciplined [...]
Satellos Reports Second Quarter 2026 Financial Results and Highlights Company Progress
13/08/2026
Reported a reduction in muscle fat fraction by MRI along with increased total effort in all TRAILHEAD participants at month six, suggestive of muscle regeneration Continued favorable safety and tolerability profile, [...]
BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026
13/08/2026
MISSISSAUGA, Ontario, Aug. 13, 2026 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its consolidated financial results for the three and six months ended June 30, 2026 on [...]
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
13/08/2026
PALO ALTO, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic [...]
Tiny Health Named No. 208 on the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies
13/08/2026
Microbiome Innovator Recognized for 1,624% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses AUSTIN, Texas, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Tiny Health , the [...]
WellBridge Surgical Named No. 988 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies
13/08/2026
Following Significant Revenue Growth Over the Past Three Years, Earning a Place Among the Nation’s Most Successful Independent Businesses INDIANAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- WellBridge Surgical today [...]
Rapport Semestriel 2026 Valneva
13/08/2026
Rapport Semestriel 2026 Valneva Pièce jointe Financial Report HY1 2026 (FR) (2026-08-12) (002)

Pages